IN2014MU01042A - - Google Patents

Download PDF

Info

Publication number
IN2014MU01042A
IN2014MU01042A IN1042MU2014A IN2014MU01042A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A IN 1042MU2014 A IN1042MU2014 A IN 1042MU2014A IN 2014MU01042 A IN2014MU01042 A IN 2014MU01042A
Authority
IN
India
Prior art keywords
compositions
component
relates
dabigatran
patients
Prior art date
Application number
Other languages
English (en)
Inventor
Sushrut Krishnaji Kulkarni
Ajaykumar Handa
Sagar Jugalkishor Baheti
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2015/000142 priority Critical patent/WO2015145462A1/fr
Priority to IN1042MU2014 priority patent/IN2014MU01042A/en
Publication of IN2014MU01042A publication Critical patent/IN2014MU01042A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1042MU2014 2014-03-26 2015-03-26 IN2014MU01042A (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2015/000142 WO2015145462A1 (fr) 2014-03-26 2015-03-26 Compositions pharmaceutiques de dabigatran
IN1042MU2014 IN2014MU01042A (fr) 2014-03-26 2015-03-26

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1042MU2014 IN2014MU01042A (fr) 2014-03-26 2015-03-26

Publications (1)

Publication Number Publication Date
IN2014MU01042A true IN2014MU01042A (fr) 2015-10-02

Family

ID=54194086

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1042MU2014 IN2014MU01042A (fr) 2014-03-26 2015-03-26

Country Status (2)

Country Link
IN (1) IN2014MU01042A (fr)
WO (1) WO2015145462A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103945A1 (fr) * 2015-12-15 2017-06-22 Strides Shasun Limited Compositions pharmaceutiques
WO2017111637A1 (fr) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Composition pharmaceutique comprenant du dabigatran ou un sel pharmaceutiquement acceptable de celui-ci
TR201617984A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
WO2019004980A2 (fr) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
TR201706848A2 (tr) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR201722323A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (fr) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
TR201905308A2 (tr) * 2019-04-09 2020-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation of dabigatran etexilate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
JP3716901B2 (ja) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
PT1870100E (pt) 2002-03-07 2012-04-17 Boehringer Ingelheim Int Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
SI2542224T1 (sl) 2010-03-01 2014-10-30 Ratiopharm Gmbh Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat
JP2015504903A (ja) 2012-01-24 2015-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の経口投与用ダビガトラン製剤
ES2895918T3 (es) 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato

Also Published As

Publication number Publication date
WO2015145462A1 (fr) 2015-10-01

Similar Documents

Publication Publication Date Title
IN2014MU01042A (fr)
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3206706A4 (fr) Composition injectable stable d'agents pharmaceutiquement actifs et procédé de préparation associé
EP3295952A4 (fr) Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
ZA201605379B (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
IL260766B (en) Continuous production of complexes containing active pharmaceutical ingredients
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
WO2014122460A3 (fr) Complexes de pémétrexed et compositions pharmaceutiques contenant des complexes de pémétrexed
EP3347022A4 (fr) Composition pharmaceutique comprenant du dutastéride et formulation en gélule la comprenant
EP3311817A4 (fr) Composition pharmaceutique permettant de prévenir et traiter des maladies de l'oeil sec, contenant l'imatinib comme principe actif
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
EP3167893A4 (fr) Compositions pharmaceutiques contenant un extrait de spirulina maxima en tant que principe actif pour la prévention et le traitement de maladies rétiniennes
EP3530654A4 (fr) Composé d'acide carboxylique à substitution quinolinyle ou sel pharmaceutiquement acceptable de celui-ci, composition pharmaceutique et utilisation associées
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
EP3425388A4 (fr) Procédé d'évaluation de la douleur causée par l'administration d'une solution de médicament, procédé de sélection d'administration de solution de médicament
EP3219311A4 (fr) Composition pharmaceutique comprenant de l'étexilate de dabigatran et procédé de préparation, préparation solide et son utilisation
ZA201901004B (en) High drug loaded tablet composition for treating hiv
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
WO2016083315A8 (fr) Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
NZ727876A (en) Misoprostol dispersible tablet